UK markets close in 5 hours 31 minutes
  • FTSE 100

    7,505.38
    -16.01 (-0.21%)
     
  • FTSE 250

    19,005.65
    -94.43 (-0.49%)
     
  • AIM

    833.70
    -6.49 (-0.77%)
     
  • GBP/EUR

    1.1592
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.2173
    +0.0040 (+0.33%)
     
  • BTC-GBP

    13,821.65
    -191.32 (-1.37%)
     
  • CMC Crypto 200

    394.81
    -6.99 (-1.74%)
     
  • S&P 500

    3,941.26
    -57.58 (-1.44%)
     
  • DOW

    33,596.34
    -350.76 (-1.03%)
     
  • CRUDE OIL

    73.63
    -0.62 (-0.84%)
     
  • GOLD FUTURES

    1,785.50
    +3.10 (+0.17%)
     
  • NIKKEI 225

    27,686.40
    -199.47 (-0.72%)
     
  • HANG SENG

    18,814.82
    -626.36 (-3.22%)
     
  • DAX

    14,265.47
    -77.72 (-0.54%)
     
  • CAC 40

    6,652.02
    -35.77 (-0.53%)
     

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S
Novo Nordisk A/S

Bagsværd, Denmark 1 November 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Under the programme initiated 3 August 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 August 2022 to 31 October 2022. The programme is now concluded.

Since the announcement 24 October, the following transactions have been made:

 

Number of
B shares

Average
purchase price

Transaction
value, DKK

Accumulated, last announcement

5,087,300

 

3,967,031,678

24 October 2022

90,000

796.05

71,644,362

25 October 2022

90,000

808.39

72,755,531

26 October 2022

90,000

806.03

72,543,018

27 October 2022

90,000

799.91

71,991,659

28 October 2022

90,000

809.01

72,810,554

31 October 2022

87,400

814.42

71,179,942

Accumulated under the programme

5,624,700

 

4,399,956,744

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 7,269 B shares in the period from 24 October 2022 to 31 October 2022. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 23,235,642 B shares of DKK 0.20 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 31 October 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 21,532,132 B shares at an average share price of DKK 771.02 per B share equal to a transaction value of DKK 16,601,725,605.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Contact for further information

Media:

 

Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

Investors:

 

Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Company announcement No 78 / 2022

Attachment